Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II study – 2012 – 2015

on behalf of the HIDES Study Group

Research output: Contribution to journalReviewResearchpeer-review

85 Downloads (Pure)

Abstract

Background It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries. Methods Individuals aged 18–65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015. Results Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5–3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis. Conclusion The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

Original languageEnglish
Article numbere0220108
JournalPLOS ONE
Volume14
Issue number8
Number of pages14
ISSN1932-6203
DOIs
Publication statusPublished - 13. Aug 2019

Fingerprint

HIV
Testing
Public health
Logistics
Infectious Mononucleosis
testing
Costs
lymphatic diseases
leukopenia
thrombocytopenia
early diagnosis
Southern European region
Eastern European region
seroconversion
public health
AIDS-Related Complex
Eastern Europe
Leukopenia
Insurance Benefits
Public Health

Cite this

@article{04d13e18482b4245a52d722b851bbc2f,
title = "Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II study – 2012 – 2015",
abstract = "Background It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1{\%}. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries. Methods Individuals aged 18–65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015. Results Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8{\%}; 95{\%} CI 2.5–3.1{\%}). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6{\%} were promptly linked to care; of these 10.4{\%} were reported lost to follow up or dead 12 months after diagnosis. Conclusion The study showed that 10 conditions had HIV prevalences > 0.1{\%}. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.",
author = "Dorthe Raben and Sullivan, {Ann Kathleen} and Amanda Mocroft and Galyna Kutsyna and Vesna Hadžiosmanović and Anna Vassilenko and Nikoloz Chkhartisvili and Viktar Mitsura and Court Pedersen and Jane Anderson and Josip Begovac and Dragsted, {Ulrik Bak} and Barbara Bertisch and Anna Grzeszczuk and Jane Minton and Necsoi, {Valentina Coca} and Maria Kitchen and Faiza Ajana and Anton Sokhan and Laura Comi and Paymaneh Farazmand and Dragica Pesut and {De Wit}, Stephane and Gatell, {Jos{\'e} Maria} and Brian Gazzard and {d’Arminio Monforte}, Antonella and Rockstroh, {J{\"u}rgen Kurt} and Yazdan Yazdanpanah and Karen Champenois and Jakobsen, {Marie Louise} and Lundgren, {Jens Dilling} and {on behalf of the HIDES Study Group}",
year = "2019",
month = "8",
day = "13",
doi = "10.1371/journal.pone.0220108",
language = "English",
volume = "14",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

Improving the evidence for indicator condition guided HIV testing in Europe : Results from the HIDES II study – 2012 – 2015. / on behalf of the HIDES Study Group.

In: PLOS ONE, Vol. 14, No. 8, e0220108, 13.08.2019.

Research output: Contribution to journalReviewResearchpeer-review

TY - JOUR

T1 - Improving the evidence for indicator condition guided HIV testing in Europe

T2 - Results from the HIDES II study – 2012 – 2015

AU - Raben, Dorthe

AU - Sullivan, Ann Kathleen

AU - Mocroft, Amanda

AU - Kutsyna, Galyna

AU - Hadžiosmanović, Vesna

AU - Vassilenko, Anna

AU - Chkhartisvili, Nikoloz

AU - Mitsura, Viktar

AU - Pedersen, Court

AU - Anderson, Jane

AU - Begovac, Josip

AU - Dragsted, Ulrik Bak

AU - Bertisch, Barbara

AU - Grzeszczuk, Anna

AU - Minton, Jane

AU - Necsoi, Valentina Coca

AU - Kitchen, Maria

AU - Ajana, Faiza

AU - Sokhan, Anton

AU - Comi, Laura

AU - Farazmand, Paymaneh

AU - Pesut, Dragica

AU - De Wit, Stephane

AU - Gatell, José Maria

AU - Gazzard, Brian

AU - d’Arminio Monforte, Antonella

AU - Rockstroh, Jürgen Kurt

AU - Yazdanpanah, Yazdan

AU - Champenois, Karen

AU - Jakobsen, Marie Louise

AU - Lundgren, Jens Dilling

AU - on behalf of the HIDES Study Group

PY - 2019/8/13

Y1 - 2019/8/13

N2 - Background It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries. Methods Individuals aged 18–65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015. Results Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5–3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis. Conclusion The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

AB - Background It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries. Methods Individuals aged 18–65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015. Results Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5–3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis. Conclusion The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

U2 - 10.1371/journal.pone.0220108

DO - 10.1371/journal.pone.0220108

M3 - Review

C2 - 31408476

AN - SCOPUS:85070559510

VL - 14

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 8

M1 - e0220108

ER -